Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | MMP1 | P03956 | 5/20 | 0.50 |
| ▸ | MMP2 | P08253 | 5/20 | 0.50 |
| ▸ | MMP9 | P14780 | 5/20 | 0.50 |
| ▸ | MMP8 | P22894 | 5/20 | 0.50 |
| ▸ | MMP13 | P45452 | 5/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.40 |
| ▸ | METAP2 | P50579 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1768004 | 0.81 | CA1 (0.53) | KMT2ACA1CA2MMP1MMP2 | |
| SCHEMBL1767675 | 0.81 | CA1 (0.53) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL18455303 | 0.78 | CA1 (0.41) | KMT2ACA1CA2MMP1MMP2 | |
| SCHEMBL1767735 | 0.78 | CA1 (0.50) | KMT2ACA1CA2MMP1MMP2 | |
| SCHEMBL15881204 | 0.78 | CA1 (0.50) | KMT2ACA1CA2MMP1MMP2 | |
| SCHEMBL29536726 | 0.77 | CA1 (0.53) | KMT2ACA1CA2MMP1MMP2 | |
| SCHEMBL11962947 | 0.77 | CA1 (0.53) | KMT2ACA1CA2MMP1MMP2 | |
| Hydrochloric Acid SCHEMBL28140803 | 0.77 | KMT2A (0.47) | KMT2ACA1CA2MEP1BEPHX2 | |
| SCHEMBL23978197 | 0.76 | CA2 (0.50) | KMT2ACA1CA2PTGES2 | |
| SCHEMBL14677037 | 0.76 | KMT2A (0.51) | KMT2AMMP1MMP2MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504003-B1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS INC (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | claimed |
| US-RE45314-E1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-12-30 | — | — | US | claimed |
| EP-2504003-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | Cardioxyl Pharmaceuticals Inc. (US) | 2012-10-03 | — | — | EP | claimed |
| US-8030356-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | claimed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | claimed |
| WO-2011063400-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | claimed |
| WO-2011063339-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | claimed |
| EP-2586434-B3 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | UNIV JOHNS HOPKINS (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20210053915-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2021-02-25 | — | — | US | disclosed |
| US-10829445-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3693363-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | The Johns Hopkins University (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3124471-B1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | UNIV JOHNS HOPKINS (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3124471-B1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | UNIV JOHNS HOPKINS (US) | 2020-06-03 | — | — | EP | disclosed |
| WO-2011063400-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063339-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| CN-101472576-A | N-hydroxysulfonamide derivatives as novel physiologically valuable nitroxyl donors | UNIV JOHNS HOPKINS (US) | 2009-07-01 | — | — | CN | disclosed |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | NATIONAL SCIENCE FOUNDATION | 2007-12-27 | — | — | US | disclosed |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | NATIONAL SCIENCE FOUNDATION | 2007-12-27 | — | — | US | disclosed |
| WO-2007109175-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | NOS2, NOS3, NOS1 | KMT2A 2073/4885CA1 3786/4885CA2 459/4885 |
| US-20210053915-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, TNNT2 | KMT2A 4748/4885CA1 2645/4885CA2 1468/4885 |
| US-10829445-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | TNNI3, TNNC1, TNNT2 | KMT2A 4748/4885CA1 2645/4885CA2 1468/4885 |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | NOS2, NOS3, NOS1 | KMT2A 1142/4885CA1 3870/4885CA2 747/4885 |
| US-20070299107-A1 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | TNNI3, TNNC1, NME4 | KMT2A 4701/4885CA1 2599/4885CA2 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.